Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,708,327
  • Shares Outstanding, K 83,513
  • Annual Sales, $ 55,830 K
  • Annual Income, $ -127,290 K
  • 60-Month Beta 1.41
  • Price/Sales 50.70
  • Price/Cash Flow N/A
  • Price/Book 141.22
Trade CYTK with:

Options Overview

Details
  • Implied Volatility 72.33%
  • Historical Volatility 47.29%
  • IV Percentile 18%
  • IV Rank 9.57%
  • IV High 289.13% on 09/24/20
  • IV Low 49.39% on 08/31/21
  • Put/Call Vol Ratio 0.64
  • Today's Volume 123
  • Volume Avg (30-Day) 735
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 2,209
  • Open Int (30-Day) 2,653

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.77
  • Number of Estimates 4
  • High Estimate -0.74
  • Low Estimate -0.79
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -1,440.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.10 +13.75%
on 09/13/21
34.45 -3.92%
on 09/17/21
+2.54 (+8.31%)
since 08/20/21
3-Month
17.72 +86.79%
on 07/14/21
34.45 -3.92%
on 09/17/21
+11.33 (+52.04%)
since 06/21/21
52-Week
14.71 +125.02%
on 10/12/20
34.45 -3.92%
on 09/17/21
+11.83 (+55.62%)
since 09/21/20

Most Recent Stories

More News
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten Supporting Progression to...

CYTK : 33.01 (+1.79%)
Cytokinetics to Participate in September Investor Conferences

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September:

CYTK : 33.01 (+1.79%)
Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host a conference call and webcast on September 13, 2021 at 8:30 AM Eastern Time to discuss the full results from REDWOOD-HCM (Randomized...

CYTK : 33.01 (+1.79%)
Spinal Muscular Atrophy Treatment Market Key Players, Industry Overview and Forecasts to 2028

Research Nester published a report titled  which delivers a detailed overview of the Spinal muscular atrophy drug market in terms of market segmentation by treatment, by route of administration, by disease...

NOVN : 8.42 (+2.06%)
PFE : 43.94 (-0.59%)
BIIB : 295.00 (-1.17%)
PTCT : 43.34 (+4.21%)
VYGR : 3.02 (+1.68%)
CYTK : 33.01 (+1.79%)
IONS : 35.95 (-0.66%)
REGN : 650.15 (+1.44%)
New Strong Sell Stocks for August 31st

AMWD, CYTK, STIM, OLLI, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on August 31, 2021.

AMWD : 64.66 (-1.84%)
CYTK : 33.01 (+1.79%)
OLLI : 65.31 (-1.15%)
STIM : 6.31 (-3.22%)
THMO : 2.19 (+1.39%)
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting

Full Results from REDWOOD-HCM Expand on Positive Topline Results of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

CYTK : 33.01 (+1.79%)
New Strong Sell Stocks for August 27th

CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021

PSTX : 7.79 (-2.38%)
CYTK : 33.01 (+1.79%)
UUUU : 7.09 (+4.73%)
IVC : 5.62 (-1.92%)
CDLX : 89.98 (+3.07%)
Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA

Cytokinetics, Incorporated (Nasdaq: CYTK) and Cure SMA today announced the renewal of their partnership to increase education, awareness, public policy and fundraising for spinal muscular atrophy (SMA)....

CYTK : 33.01 (+1.79%)
New Strong Sell Stocks for August 18th

CYTK, GEVO, ISEE, MCFE, and NOMD have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2021.

CYTK : 33.01 (+1.79%)
GEVO : 6.20 (-0.31%)
NOMD : 28.01 (+2.30%)
ISEE : 16.34 (+0.74%)
MCFE : 21.49 (+0.99%)
Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -32.31% and -49.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 33.01 (+1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 34.72
2nd Resistance Point 34.08
1st Resistance Point 33.26
Last Price 33.01
1st Support Level 31.80
2nd Support Level 31.16
3rd Support Level 30.34

See More

52-Week High 34.45
Last Price 33.01
Fibonacci 61.8% 26.91
Fibonacci 50% 24.58
Fibonacci 38.2% 22.25
52-Week Low 14.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar